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Abstract Mechanisms underlying the central regulation of food intake and fat accumulation are
not fully understood. We found that neurosecretory protein GL (NPGL), a newly-identified
neuropeptide, increased food intake and white adipose tissue (WAT) in rats. NPGL-precursor gene
overexpression in the hypothalamus caused increases in food intake, WAT, body mass, and
circulating insulin when fed a high calorie diet. Intracerebroventricular administration of NPGL
induced de novo lipogenesis in WAT, increased insulin, and it selectively induced carbohydrate
intake. Neutralizing antibody administration decreased the size of lipid droplets in WAT. Npgl
mRNA expression was upregulated by fasting and low insulin levels. Additionally, NPGL-producing
cells were responsive to insulin. These results point to NPGL as a novel neuronal regulator that
drives food intake and fat deposition through de novo lipogenesis and acts to maintain steady-
state fat level in concert with insulin. Dysregulation of NPGL may be a root cause of obesity.
DOI: 10.7554/eLife.28527.001
Introduction
Dysregulated energy balance can result in obesity and lead to serious health problems such as dia-
betes and cardiovascular disease (Steinberger and Daniels, 2003; Hill et al., 2012; Ahima and
Lazar, 2013). Thus, it is important for human health to gain insight into the physiological mecha-
nisms underlying the regulation of obesity. As obesity results mainly from overfeeding, most
research to date has focused on hypothalamic regulation of feeding and satiety. Several hypotha-
lamic neuropeptides and peripheral factors influence food intake and body mass (Schwartz and
Porte, 2005; Morton et al., 2006, 2014). For instance, the arcuate nucleus (Arc) of the
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hypothalamus produces neuropeptide Y (NPY)/agouti-related peptide (AgRP) and a-melanocyte-
stimulating hormone (a-MSH), which are potent orexigenic and anorexigenic factors, respectively
(Schwartz and Porte, 2005; Morton et al., 2006, 2014). In addition, leptin and insulin derived from
peripheral tissues act on the hypothalamus to influence energy homeostasis (Baskin et al., 1999;
Varela and Horvath, 2012). Precise hypothalamic control of energy balance affects puberty, ther-
moregulation, energy storage, survival, and other critical processes during different life-history
stages (Schneider et al., 2013). Prior to the last decade, several bioactive peptides in the brain
were discovered: neuromedin S, TLQP-21, nesfatin-1, and neuroendocrine regulatory peptide
(NERP) (Mori et al., 2005; Bartolomucci et al., 2006; Oh-I et al., 2006; Yamaguchi et al., 2007).
These neuropeptides are also involved in energy homeostasis and feeding behavior (Ida et al.,
2005; Bartolomucci et al., 2006; Oh-I et al., 2006; Toshinai et al., 2010). Recently, nonadecaneur-
opeptide derived from Acyl-CoA binding domain-containing seven was found to be a novel anorexi-
genic factor in the mouse hypothalamus (Lanfray et al., 2016). Despite considerable progress in
understanding the regulation of energy homeostasis over the last several decades, the neural control
of hyperphagia or obesity is not completely understood. To further understand the mechanism regu-
lating energy intake and/or storage, we sought to identify previously unknown bioactive substances
in the hypothalamus that regulate energy metabolism.
As part of our search for novel neuropeptides and/or peptide hormone precursors in the hypo-
thalamus, we identified a novel cDNA in the chicken hypothalamus and deduced a precursor protein
including a secretory protein of 80 amino acids (Ukena et al., 2014). This small protein has Gly-Leu-
NH2 at its C-terminal and was named neurosecretory protein GL (NPGL). In chickens, subcutaneous
infusion of NPGL increased body mass gain, suggesting that NPGL may be involved in growth pro-
cesses, including energy homeostasis (Ukena et al., 2014). Subsequently, we found homologous
Npgl genes in mammals, including human, rat, and mouse; the primary structure of NPGL is highly
conserved among mammals and avian species (Figure 1—figure supplement 1A). Rat NPGL
assumes a circular structure, although the mature structure has not been determined (Figure 1A).
Given the effects of NPGL administration observed in chickens, along with the highly conserved
nature of this gene across species, we hypothesized that NPGL and its precursor serve a prominent,
eLife digest Throughout history, our ancestors needed to accumulate fat to survive during
times when food sources were scarce. However, for most people in the modern age, food is
abundant and eating too much is a major cause of weight gain, obesity and diseases affecting the
metabolism. Obesity in particular, can lead to diseases such as diabetes and heart disease.
Hunger and appetite are regulated by proteins and other chemicals that act as messengers, for
example insulin, and a region of the brain called the hypothalamus. However, the full mechanisms
that regulate these sensations remain unclear. Only recently, a protein called NPGL was discovered
in a part of the hypothalamus of birds and mammals. However, it was not known if NPGL plays a
role in regulating eating habits and weight gain.
Iwakoshi-Ukena et al. have now discovered that NPGL is found in the hypothalamus of rats and is
regulated by diet and insulin. When the gene for NPGL was manipulated to produce too much of
the protein, rats fed a high calorie diet started to eat more, and gained more weight and body fat.
Adding additional NPGL to their brains had the same effect. When the animals were fed a normal
diet, NPGL only moderately affected how much they ate, but it substantially increased how much fat
they produced. Iwakoshi-Ukena et al. also observed that when animals were starved and insulin
levels were low, the rats started to produce more NPGL. These results suggest that NPGL plays a
role in fat storage when energy sources are limited, and can contribute to obesity when too much
NPGL is produced in animals on a high calorie diet.
These findings indicate that NPGL could be an additional brain chemical that regulates hunger
and fat storage in mammals. A next step will be to reveal the specific mechanisms by which NPGL
regulates overeating and fat accumulation. These findings will further advance the study and
treatment of obesity and obesity-related diseases.
DOI: 10.7554/eLife.28527.002
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Figure 1. Structure of NPGL and expression of NPGL in rats. (A) The amino acid structure of NPGL is shown schematically. The bold line between
cysteine residues indicates a disulfide bond. (B) Expression levels of the NPGL-precursor mRNA in the entire brain and different brain regions, including
the telencephalon, diencephalon, mesencephalon, cerebellum, and mediobasal hypothalamus (n = 4). (C) Western blot analysis of mature NPGL in the
hypothalamus. Synthetic NPGL served as a reference marker (1). The extract of the hypothalami from five rats (2). (D) Schematic representation of the
localization of NPGL-immunoreactive fibers (blue dots) and cells (red dots) in the mediobasal hypothalamus. Abbreviations; Arc: the arcuate nucleus,
ArcLP: lateroposterior part of the Arc, ArcMP: medial posterior part of the Arc, DMH: doromedial hypothalamus, f: fornix, LH: lateral hypothalamus,
PMD: dorsal premammillary nucleus, PMV: ventral premammillary nucleus, Te: terete hypothalamic nucleus, VMH: ventromedial hypothalamus, and
VTM: ventral tuberomammillary nucleus. (E–G) Photomicrographs of the cells containing NPGL-precursor mRNA in the mediobasal hypothalamus. The
squares including the ArcLP and VTM are shown magnified in (F) and (G), respectively. Arrowheads in (G) indicate signals. Scale bar = 100 mm. (H and I)
Photomicrographs of NPGL-immunoreactive cells in the ArcLP (H) and VTM (I). Arrowheads in (I) indicate signals. Scale bar = 100 mm. (J)
Photomicrograph of NPGL-immunoreactive fibers between the DMH and VMH. Scale bar = 100 mm. Mean ± s.e.m. (one-way ANOVA with Tukey’s test
as a post-hoc test: ***p<0.005).
Figure 1 continued on next page
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unexplored role in energy homeostasis in mammals. More recently, we found that NPGL could
induce food intake in mice (Matsuura et al., 2017). However, the physiological significance of NPGL
in metabolic control in mammals remains to be elucidated.
The present investigation sought to characterize whether NPGL impacts food intake and energy
metabolism using a rat model. To accomplish this goal, we first examined the pattern of expression
in the brain and peripheral tissues, along with the specific localization and distribution of NPGL-pro-
ducing cells in the brain. Subsequently, we investigated the biological action of NPGL and its precur-
sor by overexpression of the precursor gene for Npgl in the hypothalamus, and
intracerebroventricular (i.c.v.) infusion of NPGL or a specific antibody directed against this protein.
We further examined the effects of NPGL on food intake, blood chemistry, and body composition
when animals were fed normal chow, high calorie diet, or macronutrient diet. Finally, we determined
that NPGL plays a role in monitoring energetic status and appropriate adjustment of feeding and
energy metabolism.
Results
Expression of Npgl mRNA and NPGL in the hypothalamus
First, we examined the expression of Npgl mRNA in the brain and various peripheral tissues in
human, rat, and mouse. The results revealed that Npgl mRNA expression is high in the brain and tes-
tis of human and rat, but in mouse it only exhibits high expression in the brain (Figure 1—figure
supplement 1B–D).
To gain insight into the functional role of NPGL, we assessed the neuroanatomical localization of
Npgl mRNA and its mature protein in the rat brain. Npgl mRNA was exclusively expressed in the
mediobasal hypothalamus (Figure 1B). Western blot analysis demonstrated the presence of the
mature form of NPGL in the hypothalamus (Figure 1C). Histological analyses showed that both Npgl
mRNA and its mature protein were localized to the lateroposterior division of the Arc (ArcLP) and
the ventral tuberomammillary nucleus (VTM) (Figure 1D–I). Immunoreactive cells were detected only
after rats were treated with colchicine to prevent axonal transport of NPGL. NPGL-immunoreactive
fibers were observed only in the hypothalamus (Figure 1D and J). This latter result suggests that
NPGL’s physiological role is mostly limited to regulation of the hypothalamus.
Because NPGL is mainly localized to the Arc, an important feeding and energy metabolic center,
we speculated that NPGL produced in the ArcLP might be involved in the regulation of feeding
behavior and body mass. Therefore, we investigated the effects of chronic exposure to NPGL on
food intake, blood chemistry, and body composition in the following experiments.
Effects of NPGL-precursor gene overexpression on food intake, body
mass, adiposity, and blood insulin
The analysis of in vivo translation of the NPGL-precursor gene was conducted to survey the more
long-term effect on phenotype, including body mass. To explore the effects of chronic NPGL-precur-
sor gene (Npgl) overexpression in the mediobasal hypothalamus, we prepared an adeno-associated
virus (AAV) that would allow chronic expression of the NPGL precursor protein (Figure 2—figure
supplement 1A) and injected it into the hypothalamus of rats (Figure 2—figure supplement 1B
and C). We then monitored food intake (high-fat/high-sucrose diet; high calorie diet, and normal
chow) for 6 weeks (Figure 2). When we investigated the effect of Npgl overexpression in rats fed
with high calorie diet, cumulative food intake, body mass, blood insulin, and WAT mass also
markedly increased (Figure 2A–D and Table 1A).
In rats fed normal chow, daily food intake did not change until approximately 3 weeks after the
AAV injection, but then slightly increased thereafter (Figure 2—figure supplement 2A). Overall,
Figure 1 continued
DOI: 10.7554/eLife.28527.003
The following figure supplement is available for figure 1:
Figure supplement 1. Amino acid sequences and expression site of NPGL.
DOI: 10.7554/eLife.28527.004
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cumulative food intake significantly increased (Figure 2E). No overall effect on body mass was
observed (Figure 2F). Despite no effect on body mass, Npgl overexpression caused a significant
increase in the mass of WAT and the size of adipocytes (Figure 2H and Figure 2—figure supple-
ment 2B). The masses of interscapular brown adipose tissue (BAT), liver, heart, and kidney remained
unchanged (Figure 2—figure supplement 2C and D), while the masses of soleus and gastrocnemius
muscles did not increase as much as controls, as did body length (Figure 2—figure supplement 2E–
G). Blood leptin increased, but other blood measures, including insulin, did not change (Table 1B
and Figure 2G).
Effect of NPGL-precursor gene overexpression on metabolism and de
novo lipogenesis
We measured the O2 consumption (VO2) and CO2 production (VCO2) at four weeks after AAV injec-
tion in normal chow-fed rats. There were no significant differences in the VO2 and VCO2 of treat-
ment and control animals (Figure 3A and B). Although overall energy expenditure did not change,
the respiratory quotient (RQ) was significantly elevated in the Npgl overexpression group
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Figure 2. The effects of Npgl overexpression. The panels show the data obtained by the injection of AAV-based control vector (AAV-CTL) or AAV-
based NPGL-precursor gene vector (AAV-NPGL) in high calorie diet (A–D) and normal chow (E–H). (A) Cumulative food intake (n = 8). (B) The body
mass (n = 8). (C) Serum insulin levels (n = 6–7). (D) Ratios of inguinal, epididymal, retroperitoneal, and perirenal WAT mass/body mass (n = 6–7). (E)
Cumulative food intake (n = 6–7). (F) The body mass (n = 6–7). (G) Serum insulin levels (n = 6–7). (H) Ratios of inguinal, epididymal, retroperitoneal, and
perirenal WAT mass/body mass (n = 6–7) and representative photographs of retroperitoneal WAT. Scale bar = 5 cm. Mean ± s.e.m. (Student’s t-test:
*p<0.05, **p<0.01, ***p<0.005).
DOI: 10.7554/eLife.28527.005
The following figure supplements are available for figure 2:
Figure supplement 1. Construction of AAV-based vectors and verification of overexpression.
DOI: 10.7554/eLife.28527.006
Figure supplement 2. The effects of Npgl overexpression in normal chow.
DOI: 10.7554/eLife.28527.007
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(Figure 3C). The locomotor activity of the two groups did not differ (Figure 3D). Therefore, it is
likely that the elevation of RQ value after Npgl overexpression is caused either by an upregulation of
lipogenesis or downregulation of lipolysis in some tissues. To elucidate these possibilities, we ana-
lyzed the expression levels of lipogenic and lipolytic enzyme mRNAs in retroperitoneal WAT (rWAT)
and liver. Specifically, we chose acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl-
CoA desaturase 1 (SCD1), glycerol-3-phosphate acyltransferase 1 (GPAT1), and adiponutrin (ADPN)
as lipogenic enzymes, and carnitine palmitoyltransferase 1a (CPT1a), adipose triglyceride lipase
(ATGL), and hormone-sensitive lipase (HSL) as lipolytic enzymes (Shi and Burn, 2004).
We found that mRNA expression levels of Acc, Fas, Adpn, and Atgl in rWAT significantly
increased after Npgl overexpression, but no differences were detected in liver (Figure 3E). The pro-
tein level of FAS in rWAT also increased after Npgl overexpression, but the amount of phosphoryla-
tion of HSL was not different (Figure 3F–H). The fatty acid ratio of 16:1/16:0 significantly increased
in rWAT of Npgl overexpression rats, but not 18:1/18:0, showing the activation of enzymatic activity
of SCD1 (Figure 3I and J). These results indicate that the activation of NPGL-induced de novo lipo-
genesis occurs in WAT but not in liver.
Effects of i.c.v. infusion of NPGL on food intake, adiposity, and de novo
lipogenesis
In addition to the analysis in vivo translation of Npgl overexpression, we performed a 13 day chronic
i.c.v. infusion of mature small protein, NPGL (15 nmol/day) using osmotic pumps in rats fed with
high calorie diet and normal chow.
When we investigated the effects of chronic i.c.v. infusion of NPGL in rats fed with high calorie
diet, food intake in the light period, blood insulin, cholesterol, and leptin all increased without
changes in overall body mass (Figure 4A–C and Table 2A). Increases in the masses of inguinal WAT
(iWAT) and perirenal WAT were also observed under this diet (Figure 4D).
Under normal chow, although no changes in food intake, blood chemistry, including insulin, or
body mass were observed (Figure 4E–G and Table 2B), the masses of rWAT and perirenal WAT sig-
nificantly increased (Figure 4H). The induction of de novo lipogenesis in rWAT but not liver was
observed (Figure 4—figure supplement 1). In addition, acute i.c.v. injection of NPGL also induced
de novo lipogenesis in rWAT (Figure 4—figure supplement 2). Analysis of the structure-activity
Table 1. Blood chemistry during Npgl overexpression.
A. Blood chemistry during Npgl overexpression under high calorie diet.
AAV-CTL AAV-NPGL
Glucose (mg/dl) 144 ± 6.1 156 ± 6.2
Free Fatty Acid (mEq/l) 0.462 ± 0.038 0.460 ± 0.033
Triglyceride (mg/dl) 192 ± 12.7 184 ± 13.7
Cholesterol (mg/dl) 149 ± 9.6 127 ± 6.1†
Insulin (ng/ml) 3.56 ± 0.77 6.71 ± 0.90*
B. Blood chemistry during Npgl overexpression under normal chow.
AAV-CTL AAV-NPGL
Glucose (mg/dl) 105 ± 2.6 108 ± 2.6
Free Fatty Acid (mEq/l) 0.703 ± 0.028 0.618 ± 0.031†
Triglyceride (mg/dl) 202 ± 13.4 253 ± 23.9†
Cholesterol (mg/dl) 80.8 ± 4.0 85.4 ± 2.1
Insulin (ng/ml) 3.52 ± 0.21 3.77 ± 0.16
Leptin (ng/ml) 12.0 ± 0.59 18.5 ± 1.60***
Corticosterone (ng/ml) 511 ± 2.1 512 ± 2.1
†p <0.1, *p<0.05, ***p<0.005.
DOI: 10.7554/eLife.28527.008
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relationship using a C-terminal Gly extended form of NPGL (NPGL-Gly; Figure 4—figure supple-
ment 3A) and an N-terminal deletion form of NPGL [NPGL(32-80); Figure 4—figure supplement
3A] revealed that the longer form containing a disulfide bond is functional and C-terminal amidation
is not necessary for induction of adiposity (Figure 4—figure supplement 3B and C). Furthermore,
we measured the size of adipocytes in rWAT in rats fed normal chow. Infusion of 7.5 and 15 nmol/
day NPGL increased the frequency of medium (3001–4000 mm2) and large (>5001 mm2) adipocytes,
respectively, relative to vehicle controls, indicating a dose-dependent effect of NPGL (Figure 4I).
Effect of i.c.v. infusion of antibody against NPGL on lipid droplets of
WAT
To suppress the activity of endogenous NPGL, we performed a 13 day i.c.v. infusion of an antibody
directed against NPGL in rats fed high calorie diet. Although food intake and body mass did not
change (Figure 4—figure supplement 4A and B), blood cholesterol significantly decreased and the
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Figure 3. The effects of Npgl overexpression on O2/CO2 metabolism and lipogenic and lipolytic enzymes. All panels show data obtained by the
injection of AAV-based control vector (AAV-CTL) or AAV-based NPGL-precursor gene vector (AAV-NPGL) in normal chow. (A) O2 consumption (VO2)
measured in the metabolic cage (n = 6–7). (B) CO2 production (VCO2) measured in the metabolic cage (n = 6–7). (C) The respiratory quotient (RQ)
measured in the metabolic cage (n = 6–7). (D) The spontaneous locomotor activity measured by infrared ray passive sensor (n = 6–7). (E) mRNA
expression levels for lipogenic (Acc, Fas, Scd1, Gpat1, and Adpn) and lipolytic (Cpt1a, Atgl, and Hsl) enzymes in retroperitoneal WAT (rWAT) and liver
(n = 5–7). Representative photographs (F) of the western blot and protein expression levels of FAS (G) and phosphorylated HSL (pHSL) (H) in
retroperitoneal WAT (n = 6). (I) Ratio of fatty acids (16:1 and 16:0) in retroperitoneal WAT (n = 6–7). (J) Ratio of fatty acids (18:1 and 18:0) in
retroperitoneal WAT (n = 6–7). Mean ± s.e.m. (two-way ANOVA followed by Bonferroni’s test or Student’s t-test: *p<0.05, **p<0.01).
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NPGL (A–I) in high calorie diet (A–D) and normal chow (E–I), and the control IgG (CTL) or the antibody against NPGL (NPGL-Ab) in high calorie diet (J).
(A) The average of food intake during the light period, dark period, or over 24 hr (n = 8). (B) Serum insulin levels (n = 8). (C) Body mass (n = 8). (D)
Ratios of inguinal, epididymal, retroperitoneal, and perirenal WAT mass/body mass (n = 8). (E) The average of food intake during the light period, dark
period, or over 24 hr (n = 7). (F) Serum insulin levels (n = 7). (G) Body mass (n = 7). (H) Ratios of inguinal, epididymal, retroperitoneal, and perirenal WAT
mass/body mass (n = 7). (I) The frequency of various adipocyte sizes measured in 1000 mm2 areas and representative photographs in sections of
retroperitoneal WAT after the infusion of vehicle (CTL) or NPGL in normal chow (n = 4–5). Scale bar = 100 mm. (J) The frequency of various adipocyte
sizes measured in 2000 mm2 areas and representative photographs in sections of retroperitoneal WAT after the infusion of the control IgG (CTL) or
antibody against NPGL (NPGL-Ab) in high calorie diet (n = 4). Scale bar = 100 mm. Mean ± s.e.m. (Student’s t-test or one-way ANOVA with Tukey’s test
as a post-hoc test: *p<0.05, **p<0.01, ***p<0.005).
DOI: 10.7554/eLife.28527.010
The following figure supplements are available for figure 4:
Figure supplement 1. The effects of chronic i.c.v. infusion of NPGL on lipogenic and lipolytic enzymes.
DOI: 10.7554/eLife.28527.011
Figure supplement 2. The effects of acute i.c.v. injection of NPGL on lipogenic and lipolytic enzymes.
Figure 4 continued on next page
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Figure 4 continued
DOI: 10.7554/eLife.28527.012
Figure supplement 3. The effects of chronic i.c.v. infusion of synthetic analogs in normal chow.
DOI: 10.7554/eLife.28527.013
Figure supplement 4. The effects of chronic i.c.v. infusion of antibody against NPGL in high calorie diet.
DOI: 10.7554/eLife.28527.014
Table 2. Blood chemistry during chronic i.c.v. infusion of NPGL or the antibody against NPGL.
A. Blood chemistry during chronic i.c.v. infusion of NPGL under high calorie diet.
CTL NPGL
Glucose (mg/dl) 138 ± 5.7 135 ± 2.5
Free Fatty Acid (mEq/l) 0.526 ± 0.043 0.56 ± 0.066
Triglyceride (mg/dl) 101 ± 13.2 149 ± 20.9†
Cholesterol (mg/dl) 99.0 ± 5.1 120.4 ± 5.3*
Insulin (ng/ml) 2.53 ± 0.45 6.03 ± 1.22*
Leptin (ng/ml) 8.76 ± 1.0 17.07 ± 1.6***
B. Blood chemistry during chronic i.c.v. infusion of NPGL under normal chow.
CTL NPGL
Glucose (mg/dl) 123 ± 7.0 128 ± 7.2
Free Fatty Acid (mEq/l) 0.276 ± 0.017 0.289 ± 0.017
Triglyceride (mg/dl) 73.0 ± 4.5 101.7 ± 11.6†
Cholesterol (mg/dl) 66.5 ± 2.1 67.5 ± 3.4
Insulin (ng/ml) 4.51 ± 0.26 4.87 ± 0.33
Leptin (ng/ml) 8.84 ± 1.4 7.93 ± 0.70
Corticosterone (ng/ml) 523 ± 3.6 519 ± 1.4
C. Blood chemistry during chronic i.c.v. infusion of the antibody against NPGL under high calorie diet.
CTL NPGL-Ab
Glucose (mg/dl) 134 ± 2.38 137 ± 1.84
Free Fatty Acid (mEq/l) 0.529 ± 0.078 0.479 ± 0.048
Triglyceride (mg/dl) 129 ± 14.6 118 ± 18.8
Cholesterol (mg/dl) 111.9 ± 3.7 98.5 ± 4.7*
Insulin (ng/ml) 2.23 ± 0.29 2.53 ± 0.33
Leptin (ng/ml) 9.14 ± 0.85 7.24 ± 0.51†
D. Blood chemistry during chronic i.c.v. infusion of NPGL under macronutrient diet.
CTL NPGL
Glucose (mg/dl) 116 ± 4.4 124 ± 4.4
Free Fatty Acid (mEq/l) 0.359 ± 0.034 0.416 ± 0.042
Triglyceride (mg/dl) 74.4 ± 6.4 97.7 ± 7.8*
Cholesterol (mg/dl) 99.7 ± 3.5 90.8 ± 5.5
Insulin (ng/ml) 1.94 ± 0.16 3.05 ± 0.68
Leptin (ng/ml) 3.92 ± 0.32 6.24 ± 0.33***
†p <0.1, *p<0.05, ***p<0.005.
DOI: 10.7554/eLife.28527.015
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mass of iWAT and blood leptin tended to decrease (Table 2C and Figure 4—figure supplement
4C). The lipid droplets in rWAT were significantly smaller after antibody infusion than those of the
controls (Figure 4J). This result suggests that endogenous NPGL promotes adiposity, a finding in
agreement with the results observed with NPGL infusion and Npgl overexpression.
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Figure 5. Feeding behavior of macronutrient diets during chronic i.c.v. infusion of NPGL. (A) The calorie intake of macronutrient diets (total, protein,
carbohydrate, and fat) by the infusion of vehicle (CTL) or NPGL during the light period, dark period, or over 24 hr (n = 8). (B) Serum insulin levels (n = 8).
(C) Body mass (n = 8). (D) Ratios of inguinal, epididymal, retroperitoneal, and perirenal WAT mass/body mass (n = 8). (E) Ratio of the interscapular BAT
mass/body mass (n = 8). (F) Ratios of liver, heart, and kidney mass/body mass (n = 8). (G) Ratios of soleus and gastrocnemius muscle mass/body mass
(n = 8). (H) Masses of soleus and gastrocnemius muscles (n = 8). (I) mRNA expression levels for lipogenic (Acc, Fas, Scd1, Gpat1, and Adpn) and
lipolytic (Cpt1a, Atgl, and Hsl) enzymes, sterol regulatory element binding protein 1 (Srebp1), lipoprotein lipase (Lpl), Cd36, fatty acid transport protein
1 (Fatp1), Slc2a4, Gapdh, Slc2a2, glucokinase (Gk), and liver pyruvate kinase (L–Pk) in retroperitoneal WAT (rWAT) and liver (n = 7–8). Mean ± s.e.m.
(Student’s t-test: *p<0.05, **p<0.01, ***p<0.005).
DOI: 10.7554/eLife.28527.016
The following figure supplement is available for figure 5:
Figure supplement 1. The effects of chronic i.c.v. infusion of NPGL under macronutrient diets.
DOI: 10.7554/eLife.28527.017
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Effects of NPGL on selective carbohydrate intake, adiposity, blood
insulin, and de novo lipogenesis
As mentioned above, we observed that NPGL induced more potent food intake in animals fed a
high calorie diet than those fed normal chow after Npgl overexpression and i.c.v. infusion of NPGL.
Blood insulin increased only under a high calorie diet in both studies of Npgl overexpression and
NPGL infusion. This high calorie diet includes high levels of sucrose as the carbohydrate source.
Therefore, we hypothesized that NPGL may induce carbohydrate intake for the purpose of de novo
lipogenesis and increase blood insulin levels. We tested this hypothesis using ad libitum selective
feeding of macronutrient diets, protein, carbohydrate, and fat diets in the next series of
experiments.
Rats infused with NPGL increased their intake of carbohydrate diet during the light period
(Figure 5A and Figure 5—figure supplement 1). This carbohydrate feeding may result in increased
total calorie intake over 24 hr (Figure 5A and Figure 5—figure supplement 1). Blood triglyceride
and leptin increased without changes in insulin and overall body mass (Figure 5B and C, and
Table 2D). The masses of WAT also significantly increased in this experiment (Figure 5D). Although
the masses of BAT, liver, heart, and kidney remained unchanged, the mass of the soleus muscle was
lower than in controls (Figure 5E–H). In addition, mRNA expression of lipogenic enzymes increased
in rWAT, but not liver (Figure 5I). Furthermore, mRNA expression of the fatty acid transporter
(Cd36), glucose transporters (Slc2a2 or Slc2a4), and a carbohydrate metabolism gene (glyceralde-
hyde-3-phosphate dehydrogenase; Gapdh) were upregulated in rWAT or liver (Figure 5I).
Response of NPGL to fasting and insulin
To explore the role of NPGL in monitoring energetic state, the expression of Npgl mRNA was exam-
ined during a negative energy balance created through fasting. The expression of Npgl mRNA
increased in rats fasted for 48 hr, with animals showing low blood glucose and insulin levels
(Figure 6A). In addition, to manipulate blood glucose and insulin levels, we examined the expression
of Npgl mRNA in a diabetic rat model in which animals possess high blood glucose and low insulin
following i.p. streptozotocin (STZ; toxic to the beta cells of pancreas) administration. The expression
of Npgl mRNA increased in STZ-treated rats (Figure 6B). In contrast, i.p. injection of insulin reduced
the expression of Npgl mRNA (Figure 6B). These results indicate that Npgl mRNA expression is
upregulated by fasting and low insulin and downregulated by high insulin.
In the final experiment, whether NPGL-producing cells respond to insulin was investigated. I.c.v.
injection of insulin immediately induced phosphorylation of Akt, an insulin-response kinase, in NPGL
cells (Figure 6C).
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Figure 6. The changes of Npgl mRNA by fasting, streptozotocin or insulin and responsibility of NPGL-producing cells to insulin. (A) The effects of
fasting. Npgl mRNA levels in the mediobasal hypothalamus of fasted rats (n = 8). (B) The effects of streptozotocin (STZ) or insulin. Npgl mRNA levels in
the mediobasal hypothalamus after 7 days of i.p. injection of STZ (n = 7) or after 7 hr of i.p. injection of insulin (n = 6–7). (C) Induction of phosphorylated
Akt (red) in NPGL-immunoreactive cells (green) after 45 min of i.c.v. injection of insulin in overnight fasted rats. Arrowheads indicate double-labeled
cells (co-localization of phospho-Akt and NPGL). Scale bar = 100 mm. Mean ± s.e.m. (Student’s t-test: *p<0.05, **p<0.01, ***p<0.005).
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Discussion
In the present study, we detected high expression of Npgl mRNA in the human, rat, and mouse
brain, particularly in the mediobasal hypothalamus. Furthermore, we found that mature NPGL is pro-
duced in restricted hypothalamic nuclei and specifically plays a major role in food intake and fat
accumulation in rats. Obesity is a burgeoning health issue worldwide, and yet how the brain regu-
lates hyperphagia or adiposity is unclear. Under a high calorie diet including high sucrose, NPGL
stimulates feeding behavior and increases blood insulin. At this time, blood glucose levels are not
different in control and NPGL-treated groups, suggesting that insulin resistance is not induced by
NPGL. Therefore, it seems that NPGL stimulates carbohydrate intake and induces de novo lipogene-
sis because these phenomena occur readily under high carbohydrate conditions (Figure 7B). Subse-
quently, NPGL stimulates more carbohydrate usage to provide the glucose substrate for
lipogenesis, and finally accelerated carbohydrate intake increases blood insulin levels as an indirect
action of NPGL (Figure 7B). This step can recur to achieve fat accumulation in WAT efficiently
(Figure 7B). It is well known that insulin is an anabolic hormone, including its role in fat deposition in
adipocytes (Dimitriadis et al., 2011). However, as revealed in the present experiments, administra-
tion of insulin inhibits the expression of Npgl mRNA (Figure 6B). This result suggests that excess de
novo lipogenesis by NPGL may be inhibited through negative feedback action of insulin (Figure 7B).
Together, the present findings point to NPGL as a novel neuronal lipogenic factor that maintains
steady levels of fat storage in harmony with insulin. However, the excess and prolonged action of
NPGL under high calorie diet finally leads to obesity (Figure 7B). In developing or developed coun-
tries, abdominal adiposity easily leads to obesity, which is associated with an increased risk of
B A 
Figure 7. Potential role of NPGL in food intake and fat accumulation. Downward blue and upward red arrows indicate ‘inhibition’ and ‘stimulation’,
respectively and other-colored arrows demonstrate downstream events. (A) During the ordinary feeding state, NPGL stimulates de novo lipogenesis
and promotes fat accumulation of WAT. (B) In the restricted feeding state like fasting, a decrease in circulating insulin induces the expression of Npgl
mRNA and NPGL production in the hypothalamus. When food is readily available, NPGL stimulates carbohydrate intake and induces de novo
lipogenesis using available carbohydrate. Subsequently, NPGL stimulates more carbohydrate usage to provide the glucose substrate for lipogenesis.
Finally carbohydrate intake increases blood insulin levels. This step can be repeated to achieve fat accumulation in WAT efficiently. Excess de novo
lipogenesis by NPGL is inhibited through negative feedback actions of insulin to maintain steady-state fat storage in WAT. Under high calorie diet,
NPGL induces overweight and finally obesity.
DOI: 10.7554/eLife.28527.019
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metabolic syndrome and cardiovascular disease (Oliveros et al., 2014). The relationship between
the action of human NPGL and its pathophysiological status has yet to be assessed, but the con-
served nature of NPGL indicates that it is likely to play an important metabolic role in humans.
The present findings indicate that NPGL induces adiposity in WAT without remarkable changes in
overall body mass in the experiments except for Npgl overexpression under high calorie diet. This
increased fat accumulation, combined with no increase in muscle mass and body length, appears to
explain the overall lack of body mass difference between the control and NPGL-treatment groups
(Figure 2—figure supplement 2E–G and Figure 5G and H). Furthermore, this study shows that
NPGL-mediated fat accumulation principally results from de novo lipogenesis in WAT but not in liver
even when animals are fed normal chow and increases in food intake and blood insulin levels do not
occur (Figure 7A). Indeed, the data from acute i.c.v. injection of NPGL show that NPGL can induce
de novo lipogenesis in WAT rapidly (Figure 4—figure supplement 2). To our knowledge, our study
is the first report on the presence of an endogenous hypothalamic mediator whose function is to
control peripheral de novo lipogenesis independently of feeding behavior in animals. De novo lipo-
genesis is the biochemical process of converting non-lipid precursors into fatty acids for storage as
energy (Moore et al., 2014). Recent evidence suggests that de novo lipogenesis in WAT plays an
important role in maintaining metabolic homeostasis, although de novo lipogenesis in non-adipose
tissues including liver leads to ectopic lipid accumulation, lipotoxicity, and metabolic stress
(Lodhi et al., 2011; Solinas et al., 2015). In adipose tissues, glucose taken up via SLC2A4 (referred
to as GLUT4) is converted into citrate via the glycolysis system and TCA cycle (Rui, 2014;
TeSlaa and Teitell, 2014). Citrate is converted to palmitoleic acid by lipogenic enzymes including
ACC, FAS and SCD1, and eventually stored as triglycerides via GPAT1 and ADPN (Shi and Burn,
2004; Rui, 2014; Jeong et al., 2011). In addition to lipogenic enzymes, the mRNA expression of
Atgl, a lipolytic enzyme, also increased in NPGL-treated rats in the cases of three different experi-
ments of this study (Figures 3E and 5I, and Figure 4—figure supplement 1A). Furthermore, the
mRNA expression of Cd36, a fatty acid transporter, increased in WAT of NPGL-infused rats under
macronutrient diets (Figure 5I). Analyses using adipose tissue specific Atgl knockout mice and whole
body Cd36 knockout mice suggest that the fat oxidation system and fatty acid transport are
required for de novo lipogenesis in adipose tissues and liver (Mottillo et al., 2014; Clugston et al.,
2014). This result suggests that the activation of de novo lipogenesis by NPGL may be coupled with
lipolysis to accelerate fat accumulation in WAT.
In contrast with its action during a positive energy state, NPGL may act to prepare animals for a
negative energy state during food restriction, as fasting induced Npgl mRNA expression
(Figure 6A). It is well known that the expression of anabolic neuropeptides such as NPY and AgRP
are upregulated under negative energy balance (Morton et al., 2006). NPGL selectively stimulates
carbohydrate intake during the light period when rats are not typically active or feeding (Figure 5A).
Circulating insulin levels are lower at this time than during the dark period (Marcheva et al., 2010).
Taken together, our data suggest that a decrease in circulating insulin during a restricted feeding
state such as fasting may induce the expression of Npgl mRNA (Figure 7B). This mechanism of
NPGL induction may serve as a hunger signal to prepare for fat accumulation during a food available
state.
NPGL-producing cells are located in the ArcLP and the VTM in the posterior hypothalamus. In
addition, we detected NPGL-immunoreactive fibers in the anterior Arc where NPY/AgRP- or a-MSH-
producing cells are located. More recently, we found that NPGL innervated a-MSH-producing cells
and the acute i.c.v. injection of NPGL stimulated feeding behavior in mice fed with normal chow
(Matsuura et al., 2017). Taken together, NPGL may regulate the transcription or activity of these
well-known orexigenic or anorexigenic factors to modulate energy homeostasis involved in food
intake and fat accumulation in rats. In the present study, chronic i.c.v. infusion of NPGL did not
increase food intake in rats fed normal chow (Figure 4E), whereas a single injection of a lower dose
of NPGL has been shown to increase food intake in mice (Matsuura et al., 2017). The reason for
this discrepancy is unclear and future studies in which rats and mice are investigated under identical
conditions are needed to clarify whether differences exist between species in the role played by this
neuropeptide. Furthermore, the VTM is known as the origin of histaminergic neurons, and neuronal
histamine is also an anorexigenic and anti-obesity factor (Haas and Panula, 2003). Thus, it is possi-
ble that NPGL-expressing cells interact with histamine neurons to regulate fat accumulation. NPGL-
immunoreactive fibers were also detected around the dorsomedial hypothalamic nucleus (DMH) and
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ventromedial hypothalamic nucleus (VMH) (Figure 1D and J). These regions also participate in
energy homeostasis (Schwartz and Porte, 2005; Morton et al., 2006). In addition, it has been dem-
onstrated that lipogenesis and lipolysis in WAT are regulated in the mediobasal hypothalamus
through the sympathetic nervous system (Buettner et al., 2008; Scherer et al., 2011). Therefore, it
is possible that NPGL may participate in the sympathetic regulation of adiposity. Future studies are
necessary to identify the target sites and neuronal networks concerning NPGL-producing neurons.
In conclusion, the present data reveal novel molecular and functional relationships among the
hypothalamus, insulin action, and peripheral adiposity and elucidate a previously unknown role for
NPGL in energy homeostasis. Together, these findings reveal a novel neurochemical gateway where
signals from the brain and periphery converge to monitor energetic status and adjust feeding and
metabolism appropriately. The cognate receptor for NPGL has not yet been identified. The identifi-
cation of the receptor will help to elucidate the mechanisms of NPGL activity in the mammalian
brain. However, the present data bring to light an important role for NPGL in regulation of food
intake, body mass, and onset of obesity.
Materials and methods
Animals
Male Wistar rats (7 weeks old) were purchased from a commercial company (Kyudo, Saga, Japan)
and housed for one week at 23 ± 2˚C under a 12:12 hr light–dark cycle with ad libitum access to tap
water and normal chow (CE-2; CLEA Japan, Tokyo, Japan). In several studies, a high-fat/high-sucrose
diet (HFSD; 32% of calories from fat/20% of calories from sucrose, D14050401; Research Diets, New
Brunswick, NJ) was also used as a high calorie diet. In a food choice experiment, protein diet (98.5%
of calories from casein/1.5% of calories from L-cystine, D14082901; Research Diets), carbohydrate
diet (43.6% of calories from corn starch/40.6% of calories from sucrose/15.8% calories from malto-
dextrin 10, D14082902; Research Diets), and fat diet (92.2% of calories from lard/7.8% of calories
from soy bean oil, D14082903; Research Diets) were used as macronutrient diets.
All animal procedures were performed in accordance with the Guide for the Care and Use of Lab-
oratory Animals prepared by Hiroshima University (permit numbers: C11-2, C13-12, and C13-17).
Production of NPGL and antibodies against NPGL
Rat NPGL of 80 amino acid residues, its analogs NPGL-Gly and NPGL(32-80), and NPGM (Figure 1—
figure supplement 1E) were synthesized by microwave-assisted solid-phase peptide synthesis using
an automated peptide synthesizer (Syro Wave; Biotage, Uppsala, Sweden) as previously described
(Masuda et al., 2015).
Rabbit antisera were produced following our published method (Ukena et al., 2010) using syn-
thetic NPGL as the antigen. Antigen solution was mixed with Freund’s complete adjuvant and
injected into rabbits. After a booster injection, blood was collected from each rabbit and the optimal
serum with high titer was selected by a dot-blot analysis (Figure 1—figure supplement 1F). The
rabbit antibody against NPGL (RRID: AB_2636993) was purified on an NPGL-conjugated sepharose
6B column. The guinea pig antibody against NPGL (RRID: AB_2636992) was similarly produced.
Production of AAV-based vectors
We followed a previously reported method (Chen et al., 2007). The full-length open reading frame
of rat NPGL was amplified from cDNA of the MBH and inserted into pAAV-IRES-GFP expression vec-
tor (Cell Biolabs, San Diego, CA). The primers for rat NPGL were 50-CGCGGATCCACCATGACTGA
TCCTGGGA-30 for sense primer and 50-CGGAATTCTTAGCTTCGATTTCTCTTTATT-30 for antisense
primer.
AAV-based vectors AAV-DJ/8-NPGL-IRES-GFP for NPGL (AAV-NPGL) and AAV-DJ/8-IRES-GFP
for control (AAV-CTL) were produced in 293AAV cells (Cat# AAV-100; Cell Biolabs) using AAV-DJ/8
Helper Free Packaging System containing pAAV-DJ/8 and pHelper plasmids (Cell Biolabs). The triple
plasmids (AAV-DJ/8-NPGL-IRES-GFP or AAV-DJ/8-IRES-GFP, pAAV-DJ/8, and pHelper) were mixed
with the Polyethylenimine MAX transfection reagent (PEI-MAX; Polysciences, Warrington, PA); the
mixture was diluted with Opti-MEM I medium (Life Technologies, Carlsbad, CA) and added to
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293AAV cells in 150 mm dishes. Transfected cells were cultured in DMEM containing 10% fetal
bovine serum.
For the purification of AAV-based vectors, three days after transfection, the cells and superna-
tants were harvested and purified using chloroform and condensed using Amicon Ultra-4 Centrifugal
Filter Devices (100K MWCO; Merck Millipore, Billerica, MA).
For AAV titration, 1 ml of AAV solution was treated with RQ1 DNase (Promega, Madison, WI)
according to manufacturer’s directions. Virus titers were determined by quantitative PCR with EGFP
primer pairs. The primers for EGFP were 50-ACCACTACCTGAGCACCCAGTC-30 for sense primer
and 50-GTCCATGCCGAGAGTGATCC-30 for antisense primer. After titration, the AAV-based vectors
were prepared at a concentration of 1  109 particles/ml and stored at  80˚C until use.
Stereotaxic surgery
The stereotaxic coordinates used in the surgery were plotted according to the Rat Brain Atlas of
Paxinos and Watson (Paxinos and Watson, 2007). Eight-week-old rats weighing 270–310 g were
placed in a stereotaxic frame (model 963; David Kopf Instruments, Tujunga, CA) under isoflurane
anesthesia.
Overexpression
For Npgl overexpression, rats were bilaterally injected with 1 ml/site (1  109 particles/site) of AAV-
based vectors (AAV-NPGL or AAV-CTL) using a Neuros Syringe (7001KH; Hamilton) into the medio-
basal hypothalamic region with the coordinates 3.8 mm caudal to bregma, 0.6 mm lateral to midline,
and 9.8 mm ventral to skull surface. Npgl overexpression was kept for six weeks with normal chow
or twelve weeks with a high calorie diet. Npgl overexpression was confirmed by real-time RT-PCR at
the endpoint. Food intake and body weight were measured every day. The masses of WAT, BAT,
liver, heart, kidney and muscle were measured at the endpoint. Body length was measured under
isoflurane anesthesia at forty-two days after injecting AAV-based vectors.
I.c.v. chronic infusion
For the 13 day chronic infusion of NPGL or the rabbit antibody against NPGL (RRID: AB_2636993),
the infusion cannula (28 gauge, ALZET Brain Infusion Kit 1; DURECT Co., Cupertino, CA) was unilat-
erally inserted into the left lateral ventricle. The final coordinates of the cannula tips were as follows:
0.9 mm caudal to bregma, 1.5 mm lateral to midline, and 4.5 mm ventral to the skull surface.
NPGL (7.5 or 15 nmol/day) was dissolved in 30% propylene glycol and adjusted to pH 8.0 with
NaOH. The dose was determined on the basis of the previous study of galanin-like peptide
(Rich et al., 2007). For the control, the vehicle solution was employed.
The rabbit antibody against NPGL (400 ng/day) was dissolved in 10 mM phosphate-buffered
saline (PBS). The dose was based on the previous report of immunoneutralization of interleukin-6
(Donegan et al., 2014). For the control, normal rabbit IgG (400 ng/day) was infused.
The solutions were loaded into an ALZET mini-osmotic pump (delivery rate 0.5 ml/hr, model 2002
for two weeks; DURECT Co.) connected with the infusion cannula using polyethylene tubing a day
before surgery and kept overnight at 37˚C. On the day of cannula insertion, the osmotic pump was
implanted subcutaneously into the back. We confirmed that the correct infusion occurred by examin-
ing the solution remaining in the pump at the endpoint. In addition, it was also confirmed that the
remaining antibody against NPGL in the pump binds NPGL by a dot-blot analysis.
Food intake and body mass were measured every day. The mass of WAT was measured at the
endpoint on all experiments, and the masses of BAT, liver, heart, kidney and muscle were also mea-
sured at the endpoint on the experiment under macronutrient diets.
I.c.v. acute injection
For the acute injection of insulin, a guide cannula (22 gauge, C313GA; Plastics One, Roanoke, VA)
was implanted unilaterally into the left lateral ventricle. The cannula was fixed to the skull using
acrylic resin (Shofu, Kyoto, Japan). The final coordinates of the cannula tips were 0.9 mm caudal to
bregma, 1.5 mm lateral to midline, and 3.5 mm ventral to the skull surface. The injector (28 gauge,
C313LI; Plastics One) extended 1.0 mm below the tips of the guide cannula. Injections were
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delivered using a syringe (Hamilton, Reno, NV) connected by polyethylene tubing to the microinjec-
tor. The injection of reagents was done after a postoperative period of 10 days.
NPGL (5 nmol/5 ml) was dissolved in 30% propylene glycol and adjusted to pH 8.0 with NaOH.
For the control, the vehicle solution was employed. rWAT and liver were collected after 5 hr of i.c.v.
injection of vehicle or NPGL.
Regular human insulin (humulin R; Eli Lilly Japan, Hyogo, Japan) was diluted in saline. The injec-
tion doses were 10 mU/animal. Saline was used as a control. Forty-five min after insulin injection,
rats were transcardially perfused with 4% paraformaldehyde (PFA) solution.
Table 3. Sequences of oligonucleotide primers for real-time RT-PCR.
A. Sequences of oligonucleotide primers for real-time RT-PCR in human tissues.
Gene Forward primer Reverse primer Accession no.
NPGL GGAACCATGGCTTAGGAAGG CCTTAGGAGCTGAGAATATGTA NM_001102659.1
ACTB GGCACCACACCTTCTACAAT AGGTCTCAAACATGATCTGG NM_001101.3
B. Sequences of oligonucleotide primers for real-time RT-PCR in rat tissues.
Gene Forward primer Reverse primer Accession no.
Npgl GGAACCATGGCTTAGGAAGG TCTAAGGAGCTGAGAATATGCA LC003309
Acc GAGGTGGATCAGAGATTTCA TTCAGCTCTAACTGGAAAGC NM_022193.1
Fas AGGATGTCAACAAGCCCAAG ACAGAGGAGAAGGCCACAAA NM_017332.1
Scd1 TGAAAGCTGAGAAGCTGGTG CAGTGTGGGCAGGATGAAG NM_139192.2
Gpat1 CAGCGTGATTGCTACCTGAA CGGAAGGTGTGGACAAAGAT NM_017274.1
Adpn GGGCTACGCTATGTCTGAGC GAGACTGCACACGAAGGTGA NM_001282324.1
Cpt1a GGATGGCATGTGGGTAAAAG TACTGACACAGGCAGCCAAA NM_031559.2
Atgl GCTGCAAGTGGGTTTTTGAT GTGAACGGTAAGGCACAGGT NM_001108509.2
Hsl GAGACGGAGGACCATTTTGA CGGAGGTCTCTGAGGAACAG NM_012859.1
Srebp1 TCACAGATCCAGCAGGTCCCC GGTCCCTCCACTCACCAGGGT NM_001276707.1
Lpl TCTCCTGATGATGCGGATTT CAACATGCCCTACTGGTTTC NM_012598.2
Cd36 GAGGTCCTTACACATACAGAGTTCGTT ACAGACAGTGAAGGCTCAAAGATG NM_031561.2
Fatp1 GCGGCGTTCGGTGTGTAC GCACGCGGATCAGAACAGA NM_053580.2
Slc2a2 GACATCGGTGTGATCAATGC TGTCGTATGTGCTGGTGTGA NM_012879
Slc2a4 CCTCCAGGATGAAGGAAACA GGGAGAAAAGCCCATCTAGG NM_012751
Gapdh CGGCAAGTTCAACGGCACAG ACTCCACGACATACTCAGCAC NM_017008.4
Gk TTGAGACCCGTTTCGTGTCA AGGGTCGAAGCCCCAGAGT NM_001270850.1
L-Pk TGATGATTGGACGCTGCAA GAGTTGGTCGAGCCTTAGTGATC NM_012624.3
Npy TATCCCTGCTCGTGTT GATTGATGTAGTGTCGCAGA NM_012614.2
Agrp GCAGACCGAGCAGAAGATGT GACTCGTGCAGCCTTACACA NM_033650.1
Pomc TAAGAGAGGCCACTGAACAT GTCTATGGAGGTCTGAAGCA NM_139326.2
Actb GGCACCACACTTTCTACAAT AGGTCTCAAACATGATCTGG NM_031144.3
Rps18 AAGTTTCAGCACATCCTGCGAGTA TTGGTGAGGTCAATGTCTGCTTTC NM_213557.1
C. Sequences of oligonucleotide primers for real-time RT-PCR in mouse tissues.
Gene Forward primer Reverse primer Accession no.
Npgl GGAACCATGGCTTAGGAAGG TCTAAGGAGCTGAGAATATGCA LC088498
Actb GGCACCACACCTTCTACAAT AGGTCTCAAACATGATCTGG NM_007393.4
DOI: 10.7554/eLife.28527.020
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Real-time RT-PCR
To survey Npgl mRNA expression in human, rat, and mouse tissues, multiple tissue cDNA panels
were employed according to the manufacturer’s directions (Clontech Laboratories, Mountain View,
CA). In addition, the whole brain, telencephalon, diencephalon, mesencephalon, cerebellum, MBH,
rWAT, and liver were dissected from rats and snap frozen in liquid nitrogen for RNA processing at
the endpoint of NPGL infusion and Npgl overexpression. RNA was extracted using TRIzol reagent
for brain tissues and liver (Life Technologies) or QIAzol lysis reagent for adipose tissues (QIAGEN,
Venlo, Netherlands) following the manufacturer’s instructions. First-strand cDNA was synthesized
from total RNA using a ReverTra Ace kit (TOYOBO, Osaka, Japan).
The sequences of primers used in this study are listed in Table 3. PCR amplifications were con-
ducted with THUNDERBIRD SYBR qPCR Mix (TOYOBO) using the following conditions: 95˚C for 20
s, followed by 40 cycles of 95˚C for 3 s, and 60˚C for 30 s. The PCR products in each cycle were mon-
itored using a StepOne Real-Time Thermal Cycler (Life Technologies). Relative quantification of each
gene was determined by the 2 DDCt method using b-actin (Actb) for brain tissues and liver or ribo-
somal protein S18 (Rps18) for rWAT as internal controls.
Sampling procedures of MBH
Npgl mRNA levels in several conditions were measured. For food deprivation, MBH was harvested
from forty-eight hours fasted rats and frozen down immediately in liquid nitrogen. The control rats
were fed with ad libitum. For induction of experimental diabetes, rats were injected i.p. with strepto-
zotocin (50 mg/kg; Sigma–Aldrich, St. Louis, MO). One week after injection when blood glucose lev-
els were higher in the streptozotocin-injected rats, MBH was collected. For injection of insulin, rats
were injected i.p. with regular human insulin (3 U/kg, humulin R) after overnight fasting. Seven hours
after injection, MBH were harvested. Blood glucose levels were lower in the insulin-injected rats at
this time. Npgl mRNA expression levels in MBH were measured by real-time RT-PCR.
Western blot analysis
For the detection of mature NPGL in the hypothalamus, the hypothalami from five rats were boiled
and homogenized in 5% acetic acid. The homogenate was centrifuged at 10,000  g for 20 min at
4˚C and the precipitate was collected. After extraction with dimethyl sulfoxide, the supernatant was
passed through a disposable C18 cartridge column (Sep-Pak Vac; Waters, Milford, MA). The retained
material was subjected to reversed-phase HPLC using a C4 column (Protein C4-300, 4.6  150 mm;
Tosoh, Tokyo, Japan) with a linear gradient of 35–75% acetonitrile containing 0.1% trifluoroacetic
acid for more than 80 min at a flow rate of 0.5 ml/min. The fractions were evaporated, dissolved in
SDS sample buffer, and subjected to 15% SDS-PAGE. After transfer onto polyvinylidene fluoride
membrane (Immobilon-P; Merck Millipore), the blot was probed with the rabbit antibody against
NPGL (RRID: AB_2636993, 1:1000 dilution) and incubated with horseradish peroxidase-labeled don-
key anti-rabbit IgG (RRID: AB_772206, 1:1000 dilution, Cat# NA934; GE Healthcare, Little Chalfont,
England). The protein bands were detected by ECL Prime (GE Healthcare) or ECL Pro (PerkinElmer,
Waltham, MA) western blotting detection reagents.
For the detections of FAS, phospho-HSL (pHSL) and total HSL in rWAT, the tissue was homoge-
nized in ice-cold RIPA buffer (Thermo Fisher Scientific, Waltham, MA), Halt Protease Inhibitor Cock-
tail, EDTA-Free (Thermo Fisher Scientific) and centrifuged at 10,000  g for 20 min to remove the
lipids. Protein content in the aqueous solution was measured using the Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific) with BSA as a standard, 30 mg-aliquots were subjected to 6% SDS-PAGE.
The western blot procedure was similar to the one described above. The antibodies against FAS,
pHSL, total HSL, and a-tubulin as an internal control were employed for FAS (RRID: AB_2100801,
1:1000 dilution, Cat# 10624–2-AP; Proteintech, Chicago, IL), pHSL (RRID: AB_490997, 1:500 dilution,
Cat# 4126; Cell Signaling Technology, Danvers, MA), total HSL (RRID: AB_2296900, 1:500 dilution,
Cat# 4107; Cell Signaling Technology), and for a-tubulin (RRID: AB_10598496, 1:2000 dilution, Cat#
PM054; Medical and Biological Laboratories, Nagoya, Japan).
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Histological analysis
In situ hybridization
Rats were transcardially perfused with 4% PFA solution and the brains were post-fixed overnight at
4˚C and then put in a refrigerated sucrose solution (30% sucrose in 10 mM phosphate buffer) until
they sank. The brain tissues were embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek,
Tokyo, Japan), sectioned coronally to a thickness of 16 mm with a cryostat at  20˚C, and then
mounted on slides. The in situ hybridization procedure was similar to that previously described
(Ukena et al., 1999, 2008).
Digoxigenin (DIG)-labeled antisense and sense RNA probes were used. The DIG-labeled RNA
probes were produced from a portion of the NPGL precursor cDNA using the DIG-RNA labeling kit
[SP6/T7] (Roche Diagnostics, Basel, Switzerland). The DIG-labeled sense RNA probe, which was com-
plementary to a sequence of the antisense probe, was used as a control to verify specificity.
The brain sections were rehydrated with PBS and treated with 0.2 N HCl for 20 min, followed by
incubation with 1 mg/ml proteinase K at 37˚C for 10 min. After fixation with 4% PFA in PBS for 5 min,
the slides were incubated in 40% deionized formamide in 4  SSC (1  SSC = 150 mM NaCl and 15
mM sodium citrate, pH 7.0) for 30 min. Hybridization was performed at 50˚C overnight with the DIG-
RNA probe mixture dissolved in the hybridization medium containing 10 mM Tris-HCl (pH 7.4), 1
mM EDTA, 0.6 M NaCl, 10% dextran sulfate, 1 Denhardt’s solution, 250 mg/ml yeast tRNA, 125
mg/ml salmon sperm DNA, and 40% deionized formamide. The sections were washed six times with
50% formamide/2  SSC at 55˚C for 10 min and treated with blocking solution (1% BSA, 1% normal
goat serum, 0.3% Triton-X100 in PBS). They were then incubated with alkaline phosphatase-labeled
rabbit anti-DIG antibody (RRID: AB_514497, 1:1000 dilution, Cat# 11093274910; Roche Diagnostics)
for 1 hr. Subsequently, the sections were washed three times for 10 min in 0.075% Brij35 in PBS. Sig-
nals were detected after the immersion of the sections overnight in NBT/BCIP stock solution (1:50
dilution in alkaline buffer; 0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl, 50 mM MgCl2) under a microscope
(Eclipse E600; Nikon, Tokyo, Japan).
Immunohistochemistry
The brain tissues were fixed as described above and then sectioned into 30 mm slices for the free-
floating method as previously described (Ukena et al., 1998). In some cases, colchicine injections
(100 mg, i.c.v.) were administered two days before sacrifice.
For the immunohistochemical staining of NPGL, endogenous peroxidase activity was eliminated
from the sections by incubation with 3% H2O2 in absolute methanol for 30 min. After blocking non-
specific binding components with 1% normal goat serum and 1% BSA in PBS containing 0.3% Triton
X-100 for 1 hr at room temperature, the sections were incubated with the rabbit antibody against
NPGL (RRID: AB_2636993, 1:1000 dilution) overnight at 4˚C. The primary immunoreaction was exe-
cuted by incubation with biotinylated goat anti-rabbit IgG (RRID: AB_2313606, 1:1000 dilution, Cat#
BA-1000; Vector Laboratories, Burlingame, CA). Immunoreactive products were detected with an
ABC kit (VECTASTAIN Elite Kit; Vector Laboratories), followed by diaminobenzidine reaction. Speci-
ficity control was obtained by preadsorbing the working dilution of the primary antibody with a satu-
rating concentration (10 mg/ml) of NPGL or its paralogous protein, NPGM (Figure 1—figure
supplement 1G L). The localization of immunoreactive cells was studied using a microscope.
For the double-immunohistochemical staining of NPGL/phospho-Akt, permeabilization was per-
formed by methanol for 30 min. After blocking nonspecific binding components with 1% normal
donkey serum and 1% BSA in PBS containing 0.3% Triton X-100 for 1 hr at room temperature, the
sections were incubated with guinea pig antibody against NPGL (RRID: AB_2636992, 1:200 dilution)/
rabbit antibody against phospho-Akt (RRID: AB_2315049, 1:400 dilution, Cat# 4060; Cell Signaling
Technology, Danvers, MA) overnight at 4˚C. Alexa Fluor 488-conjugated donkey anti-guinea pig IgG
(H+L) (RRID: AB_2340472, 1:600 dilution, Cat# 706-545-148; Jackson ImmunoResearch, West Grove,
PA) and Cy3-conjugated donkey anti-rabbit IgG (RRID: AB_2307443, 1:400 dilution, Cat# 711-165-
152; Jackson ImmunoResearch) were used as a secondary antibody.
Hematoxylin and eosin staining
rWAT was soaked in 4% PFA at the endpoint of NPGL infusion and Npgl overexpression, embedded
in Neg-50 Frozen Section Medium (Thermo Fisher Scientific), and sectioned to a thickness of 20 mm
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with a cryostat at  30˚C. The sections were then air-dried and delipidated with acetone. The nucleus
and cytoplasm were stained with hematoxylin and eosin (5 min for each stain), and the sections were
washed in tap water. After dehydration with alcohol series and clearing with xylene, the sections
were mounted on slides and examined under a microscope.
Measurement of adipocyte size
The slides were photographed under a light microscope. For rWAT analysis, two regions were ran-
domly selected from each slide and diameters of approximately 100–250 adipocytes were obtained
by averaging the largest and smallest diameters. Two independent investigators who were blind to
the groups performed all analyses.
Indirect calorimetry and locomotor activity
Four weeks after injecting AAV-based vectors, indirect calorimetry was performed using an O2/CO2
metabolism-measuring system for small animals (MK-5000RQ; Muromachi Kikai, Tokyo, Japan). The
system monitored VO2 (ml/min) and VCO2 (ml/min) at 3 min intervals and calculated the respiratory
quotient (RQ) ratio (VCO2/VO2). Locomotor activity was simultaneously measured using the Super-
Mex infrared ray passive sensor system (Muromachi Kikai). Measurements were collected hourly over
a 23 hr period (light period: 10:00–21:00, dark period: 21:00–9:00) after habituation for 30 min.
Energy expenditure was calculated using the following equation: energy expenditure (cal/kg/hr) =
VO2 (ml/kg/hr)  [3.815 + (1.232  RQ)] (Lusk, 1928).
Fatty acid analysis
For the analysis of endogenous SCD1 activity in rWAT, the lipids were extracted according to the
previous method (Folch et al., 1957). WAT (100 mg) was extracted with 1 ml of chloroform: metha-
nol (2:1) using beads crusher (mT-12; TAITEC, Saitama, Japan) and 0.25 ml of distilled water was
added and mixed by inversion. After incubation for 30 min, the sample was centrifuged at 3000  g
and the lower organic phase was collected and evaporated. Extracted fatty acids were methylated
using Fatty Acid Methylation Kit (nacalai tesque, Kyoto, Japan) and purified using Fatty Acid Methyl
Ester Purification Kit (nacalai tesque). The eluted solution was evaporated to dryness and kept at –
20˚C. The residues were resolved into hexane and fatty acids were identified by GC-MS (JMS-T100
GCV; JEOL, Tokyo, Japan). The SCD1 activity was estimated as oleate to stearate ratio (18:1/18:0)
and palmitoleate to palmitate ratio (16:1/16:0) from individual fatty acids. The 16:1/16:0 ratio seems
to be a better indicator of endogenous SCD1 activity than the 18:1/18:0 ratio (Sampath and
Ntambi, 2008).
Blood tests
Serum levels of glucose, lipids, and hormones were measured using appropriate equipment,
reagents, and kits. The GLUCOCARD G+ meter was used to measure glucose content (Arkray,
Kyoto, Japan). The NEFA C-Test Wako (Wako Pure Chemical Industries, Osaka, Japan) was used to
measure free fatty acid levels. The Triglyceride E-Test Wako (Wako Pure Chemical Industries) was
used to measure triglyceride levels and the Cholesterol E-Test Wako (Wako Pure Chemical Indus-
tries) for cholesterol content. The Rebis Insulin-rat T ELISA kit (Shibayagi, Gunma, Japan) was used
to measure insulin levels, the Leptin ELISA kit (Morinaga Institute of Biological Science, Yokohama,
Japan) for leptin, and the Corticosterone ELISA kit (Assaypro, St. Charles, MO) for corticosterone.
Blood chemistry is listed in Tables 1 and 2.
Statistical analysis
Data were analyzed using the student’s t-test or two-way analysis of variance (ANOVA) followed by
Bonferroni’s test for two groups. In addition, data from three or six groups were statistically analyzed
using one-way ANOVA with Tukey’s post-hoc test as appropriate. Statistical significance was set at
p<0.05. All results are presented as the mean ± standard error of the mean (± s.e.m.).
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